AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04763473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avocado extract
Description: Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
Study NCT04763473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 10 grams of corn meal daily for 12 weeks.
Study NCT05660850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDC-6599-matching placebo
Description: GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets
Study NCT05660850 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7
Study NCT05623202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level behavior-change intervention to strengthen food- and diet-related capital to promote food security and diet quality among low-income Hispanic/Latino adults
Description: The behavior-change intervention with low-income Hispanic/Latino adults will mobilize existing sources of human, material, social, and cultural capital at the individual, household, social, and community level, and will include a nutrition education component and a food access component.
Study NCT05077631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACD856
Description: Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
Study NCT05077631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution
Study NCT05077631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACD856 (fed cohort)
Description: Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
Study NCT04879355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal needle (25G)
Description: Fine needle aspiration from thyroid nodules using a 25G spinal needle.
Study NCT04879355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fine needle (25G)
Description: Fine needle aspiration from thyroid nodules using a conventional 25G fine needle
Study NCT05516134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE at Home
Description: The All About Me (AAM) app will consist of Serious Digital Health Games for PWD. The market-ready version of the app will consist of five components. (1) The Fun Facts About Me Game will be used when a PWD is moving into LTC. The goal of the game is to provide an enjoyable way for family members and PWD to provide important information about the PWD's background. (2) The Resident Game Bundle will consist of SDHGs that will allow PWD to learn about one another in an enjoyable way. (3) The My Residents Module will provide staff with a convenient way to view information about a PWD with whom they will be working. Staff will launch this module from any device. (4) The Meet the Staff Module, which will be developed and tested in a future Phase II study, will allow residents to learn about staff members at their community. (5) The AAM Training Modules will provide staff and family members with access to video-based training modules that describe how to use relevant portions of the app
Study NCT05665751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-3595 Dose 1
Description: Tablets administered orally
Study NCT05665751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-3595 Dose 2
Description: Tablets administered orally
Study NCT05665751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally
Study NCT05168969 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).
Study NCT06008067 — intervention group
Intervention type: RADIATION
Intervention: tricuspid annular plane systolic excursion (TAPSE)
Description: Echocardiography
Study NCT06351748 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.
Study NCT03706131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical mobilisation
Description: manual therapy
Study NCT05331625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Offering Additional Resources to Promote Symptom Management
Description: Participants will be offered additional resources to promote symptom management.
Study NCT05395767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Anterior Cruciate Ligament reconstruction using living donor hamstring allograft from a parent donor
Description: The Parent donor will undergo hamstring tendon graft harvest under general anaesthesia in a routine fashion in one theatre. The Graft material will be transported thorough to the adjacent theatre, where the child will be anaesthetised and undergoing arthroscopy of their injured knee in preparation for receiving the graft. ACL reconstruction Surgery will be undertaken in the child recipient as per the Surgeons usual technique, +/- meniscus repair +/- lateral tenodesis as required.
Study NCT05353309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Angioplasty
Description: Angioplasty Iliac done following standard practice
Study NCT05353309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty with D images
Description: Angioplasty Iliac under additional 3D Images merged as surgery support
Study NCT06143774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-920 Oral Gel (10 mg and 30 mg)
Description: TRX-920 Oral Gel will be administered orally at a week (BIW) in an 8-week cycle. No food should be taken 2 hours before and 1 hour after taking TRX-920. The dose escalation/de-escalation rules will be based on definitions of dose-limiting toxicity (DLT) and will be monitored during the first treatment cycle (i.e., the first 4 weeks post the first dose).~The starting dose will be 1 mg and the dosing frequency is twice every week (BIW). Subjects will be assigned to a dose level in sequential cohorts based on the order of their enrollment. The dose escalation will follow a 3+3 design and doses escalate from approximately 1 mg BIW, 2 mg BIW, 4 mg BIW, 8 mg BIW, and 16mg BIW and the doses for subsequent cohorts will be determined by Safety Review Committee (SRC). Dose escalation will be stopped till the maximum tolerated dose (MTD) is reached or identified.
Study NCT06639308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Flexor Hallucis longus tendon transfer to tendon achilles
Description: The endoscopic FHL tendon transfer is usually performed with the scope introduced through the posterolateral portal and instruments through the posteromedial portal. The FHL tendon must be identified during hindfoot working area creation. First, the calcaneoplasty is completed as described. Next, the FHL tendon is harvested. A tunnel was created into calcenous the tendon is introduced into the tunnel and the tendon is secured with an interference screw of same size than the tunnel
Study NCT06639308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flexor Hallucis longus transfer to tendon achilles
Description: The FHL tendon can be approached through the posterior longitudinal incision The FHL is confirmed by digital retraction of the tendon, watching for flexion of the hallux. Dissection of the FHL tendon is followed to the posterior talus and FHL tunnel, remaining lateral to avoid the neurovascular bundle. Release of the fibro-osseous tunnel along the posterior talus is necessary to gain length. With the hallux and ankle plantar flexed, the FHL tendon is transected as distally as possible. The tendon is fixed to the calcaneus just anterior to the Achilles stump insertion by an interference screw.
Study NCT06463574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-adhesive resin restoration
Description: Light cured, hybrid resin composite material which contains polymerization modulator that lessens its degree of polymerization shrinkage
Study NCT06463574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-adhesive resin restoration
Description: Light cured, hybrid resin composite material which contains polymerization modulator that lessens its degree of polymerization shrinkage
Study NCT04592744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II infusion for Intraoperative management during liver transplantation
Study NCT04592744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
Study NCT06299709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC tablet for oral administration.
Study NCT06299709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC granules for oral administration.
Study NCT06251895 — intervention group
Intervention type: OTHER
Intervention: DKA protocol
Description: IV fluids and IV insulin as per guidelines. reference 1-2
Study NCT04592744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
Study NCT05144204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Description: Low FODMAP diet instruction to irritable bowel syndrome patients.
Study NCT06316115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In Patıents Wıth Dıabetıc Foot Ulcer, Effect On Paın And Anxıety Of Stress Ball Use Durıng Sharp Debrıdement
Description: Patients in this group participating in the study will be given a stress ball and asked to use it before the debridement procedure, and each patient will be debrided by the same person throughout the procedure. The patient's pain and anxiety will be evaluated by a nurse independent of the research before and after the debridement procedure.
Study NCT05357547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone 20mg
Description: Buspirone tablets in opaque capsule. Used as probe for 5HT1A agonism
Study NCT05357547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Lactose-sucrose tablets in opaque capsule
Study NCT06324448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS self-administered at home once a day for 28 consecutive days for a total of 28 sessions (one session consists of 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea)).
Study NCT06680609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nefopam 20 MG/ML
Description: The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing nefopam 20 mg was infused over 20 min
Study NCT06680609 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing placebo diluted with normal saline was infused over 20 min
Study NCT06681688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}
Description: Eyes in the Study Arm will be treated with the following intraoperative interventions: Intracameral (OMIDRIA) phenylephrine 1.0%/ketorolac 0.3%, intracameral moxifloxacin (0.5%), and subconjunctival triamcinolone acetonide (0.4 mL, 10mgs/mL).
Study NCT06681688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
Description: On the Day of Surgery, eyes in the Control Arm will receive in-office drops administered by study staff according to the following schedule:~* In pre-operative holding: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* Immediately prior to surgery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* At the conclusion of surgery while still in the operating room: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)~* Any time in postoperative recovery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)
Study NCT06680154 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current was delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) were used throughout the stimulation. Before placing the electrodes on the head, the subject's hair was moved to the side
Study NCT06680154 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta burst stimulation
Description: the intermittent theta burst stimulation (iTBS) which is regarded as safe for high-frequency neuromodulation. Compared to classical rTMS, where pulses are applied repeatedly at a fixed frequency, iTBS consists of bursts of pulse triplets. In the classical protocol, the bursts are applied for two seconds in 5Hz intervals followed by an eight-second break, before the next bursts are applied. This pattern is repeated for 190 seconds resulting in 600 pulses per protocol.
Study NCT06680154 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: In the case of sham TMS, two different sham coils (double 70mm pCool-SHAM coil, Mag\&More GmbH, Munich, Germany) will produce audible clicks at the decibel intensity corresponding to an active coil without the induction of an electromagnetic pulse. Sham tACS will be applied by only ramping the current for 15 seconds up and 15 seconds down at the beginning and end of the stimulation respectively.
Study NCT06310525 — intervention group
Intervention type: OTHER
Intervention: Drowning incident
Description: Drowning was defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid.
Study NCT06614829 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stratafix Suture
Description: Stratafix sutures are barbed and have an antimicrobial coating. The barbs maintain tension during and allows for knotless suturing. The antimicrobial coating inhibits bacterial colonization of the wound.
Study NCT06614829 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DERMABOND PRINEO
Description: DERMABOND™ PRINEO™ Skin Closure System is a sterile, liquid topical skin adhesive. It also incorporates a self-adhering mesh that is applied to the approximated skin edges to provide temporary skin edge alignment until the liquid adhesive is applied to achieve skin closure. It forms a strong, flexible, waterproof microbial barrier-as long as the adhesive film remains intact-that falls off naturally after 7-14 days.~Dermabond Prineo system will be applied to the skin for skin closure.
Study NCT06680739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV every 4 weeks
Study NCT06680739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 300 mg IV as a single dose
Study NCT06640062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Patients received ultrasound-guided erector spinae plane block.
Study NCT06640062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oblique subcostal transversus abdominis plane block
Description: Patients received ultrasound-guided oblique subcostal transversus abdominis plane block.
Study NCT06637007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide Tablets combined with AK112
Description: Chidamide Tablets 30mg/day, po.Bid; AK112（10mg/kg or 20mg/kg）, ivgtt, Q3W.
Study NCT06637839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Locomotor Training Program
Description: The moderate-intensity program prescribes participants to exert 50-59% of their heart rate (HR) reserve, or a score of 13-15 on Borg's rating of perceived exertion (RPE) scale.
Study NCT04508335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reia Vaginal Pessary
Description: Reia Vaginal Pessary
Study NCT06708754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) Therapy
Description: PBM is a low-intensity form of light therapy and employs visible or near-infrared (NIR) light generated from a laser or Light Emitting Diode (LED).~In this study, PBM will be delivered using an LED device emitting 660 and 850nm with the purpose of research. The output power typically ranges from 5 to 200 mW with wavelengths ranging 600-1,000nm.
Study NCT06708754 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PBM
Description: Sham PBM will be delivered using a matching shame device that emits no output power.
Study NCT06707246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 MG; Tofacitinib 11mg
Description: Tofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml
Study NCT06708143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporal Interference
Description: Researchers apply temporal interference (TI) stimulation to the deep brain nuclei of drug resistant epilepsy patients.
Study NCT06708845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zamtocabtagene autoleucel
Description: chimeric antigen receptor T-cell (CAR-T) therapy
Study NCT06708845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy
Study NCT06708845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy
Study NCT06709586 — intervention group
Intervention type: PROCEDURE
Intervention: Thermal ablation
Description: Thermal ablation is a treatment for secondary hyperparathyroidism. There are radiofrequency ablation (RFA) and microwave ablation (MWA). For RFA, an electrode needle is inserted into the parathyroid under imaging guidance. High - frequency current heats the tissue to cause necrosis. MWA uses electromagnetic waves to generate heat by friction. Before ablation, imaging and lab tests are done for evaluation. During the process, precise positioning and real - time monitoring are key. After that, patients are observed for bleeding, swelling and other symptoms, and tests are repeated to assess the effect.
Study NCT06709586 — intervention group
Intervention type: PROCEDURE
Intervention: parathyroidectomy
Description: Parathyroidectomy for secondary hyperparathyroidism is a common approach. The surgeon first makes an incision in the neck area under general or local anesthesia. Then, the enlarged parathyroid glands are carefully identified and dissected. Precise surgical skills are required to avoid damaging nearby structures such as the recurrent laryngeal nerve and blood vessels. After the removal of the abnormal parathyroid tissue, the wound is closed.
Study NCT06710704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous pulsed radiofrequency
Description: Patients underwent transcutaneous PRF at the affected elbow.
Study NCT06710704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone and mepacaine
Description: Patients received intraarticular injections of methylprednisolone (40 mg/ml) with 1 ml mepacaine at the point with utmost tenderness in the lateral epicondyle area under aseptic conditions.
Study NCT06707311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients received calcium hydroxide with glass ionomer restorative material
Description: patients received calcium hydroxide with glass ionomer restorative material
Study NCT06707311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients received TheraCal LC with glass ionomer restorative material
Description: patients received TheraCal LC with glass ionomer restorative material
Study NCT06707311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients received bioactive bonding with glass ionomer restorative material
Description: patients received bioactive bonding with glass ionomer restorative material
Study NCT06707311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patients received universal bonding with glass ionomer restorative material
Description: patients received bioactive bonding with glass ionomer restorative material
Study NCT06373250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Membrane stripping group
Description: An information form will be filled in for admission to the Primipar participating maternity unit. Membrane stripping will be performed during a vaginal examination at least once during the birth process. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the visual analogue scale and Bishop scores obtained during the vaginal examinations will be taken. At four hours postpartum, the pads are weighed and the amount of bleeding is recorded on the form. You will also be asked to complete the short form of the Birth Satisfaction Scale.